MARKET

EYES

EYES

Second Sight Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8907
-0.0165
-1.82%
After Hours: 0.8886 -0.0021 -0.24% 17:04 08/07 EDT
OPEN
0.9000
PREV CLOSE
0.9072
HIGH
0.9060
LOW
0.8697
VOLUME
273.10K
TURNOVER
--
52 WEEK HIGH
8.96
52 WEEK LOW
0.7100
MARKET CAP
20.59M
P/E (TTM)
-0.4237
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EYES stock price target is 2.500 with a high estimate of 2.500 and a low estimate of 2.500.

EPS

EYES News

More
EYES, SOLO, FOSL and VAL among midday movers
Seeking Alpha - Article · 06/09 16:45
M, OPK among premarket gainers
Seeking Alpha - Article · 06/09 13:16
Second Sight Medical Products (EYES) Upgraded to Buy: Here's What You Should Know
Second Sight Medical Products (EYES) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 06/03 16:00
Second Sight Medical Products (EYES) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks · 05/13 17:30
Second Sight Medical Products Inc. Announces Closing of Public Offering of Common Stock
Business Wire · 05/05 18:08
Second Sight Medical Products Announces The Closing Of Common Stock Offering Of 7.5 Million Shares At $1 Per Share
Benzinga · 05/05 17:09
WDC, CCL among premarket losers
Seeking Alpha - Article · 05/01 13:17
Second Sight Medical Products Prices 7.5M Share Public Offering of Common Stock @$1.00/Share
Second Sight Medical Products Inc.
Benzinga · 05/01 09:42

Industry

Medical Equipment, Supplies & Distribution
+0.52%
Healthcare Equipment & Supplies
+0.49%

Hot Stocks

Symbol
Price
%Change

About EYES

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.
More

Webull offers kinds of Second Sight Medical Products Inc stock information, including NASDAQ:EYES real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYES stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EYES stock methods without spending real money on the virtual paper trading platform.